Purpose: Transnasal administration is one of the most common routes for allergen challenge in mouse models of airway diseases. Although this technique is widely used, neither the amount of allergen that reaches the lung nor its airway distribution has been well established. We used positron emission tomography (PET) and computed tomography (CT) to examine the anatomical distribution of a solution containing a tracer immediately after transnasal delivery and to determine the possible influence of age and administered volume. Procedures: Forty-six female BALB/c mice were divided into three groups according to instillation volume and age: (A) 15 μl, 8-10 weeks old (N=10), (B) 30 μl, 8-10 weeks old (N= 20), and (C) 30 μl, 32 weeks old (N=16). Anesthetized animals underwent a dynamic scan in a dedicated small-animal PET scanner immediately after transnasal administration of a solution containing 18 FDG. Regions of interest were used to obtain quantitative data. Animals were also imaged with a small-animal CT scanner to obtain complementary anatomical information. Results: Mean±SD (5.69±4.51%) of the solution administered reached the lungs in group A, 41.84±8.03% in group B, and 36.65±16.15% in group C. A comparable percentage was delivered to the left and right lungs in all the groups. Analysis of variance revealed a significant difference between the groups in the proportion of the solution that reached the lungs depending on the injection volume (PG0.001), but not depending on animal age. Conclusions: In this first report on quantitative imaging by PET and CT in small animals, we confirmed the suitability of the transnasal route with an instilled volume of 30 μl delivering fluids into the lower airways, although only about 40% of the dose reaches the lungs.
Introduction
A llergic bronchial asthma is a chronic inflammatory disease with an increasing worldwide prevalence.
Current pharmacologic therapies provide nonspecific shortterm relief from symptoms, but the efficacy of etiological treatments based on allergen immunotherapy is still limited. Nowadays, many asthma studies focus on reducing morbidity. However, ethical restrictions on human studies make murine models particularly useful, since it has been demonstrated that the allergic response in mouse lungs closely resembles certain aspects of human asthma [3] .
Experimental protocols for airway allergen challenge in these models of airway disease involve three main routes of administration: (1) transnasal [4] , (2) intratracheal [7] , and Correspondence to: M Desco; e-mail: desco@mce.hggm.es (3) inhaled [11, 12, 18] . Our study focuses on transnasal administration. Although the procedure has been widely used, neither the amount of allergen that reaches the lungs nor the distribution within the airways has been well established.
Positron emission tomography (PET) is a noninvasive imaging technique that allows for reliable measurement of the concentration of radiotracers in the body of a living subject. Recent advances in detector design have enabled the construction of high-resolution, small-animal PET scanners for imaging small laboratory animals, thus opening new areas of research on the brain, tumors, preclinical evaluation of new radiopharmaceuticals, as well as gene expression and gene therapy [15, 17] .
Computed tomography (CT) is also a noninvasive imaging technique that uses X-rays to provide anatomical information. Image contrast depends on the attenuation coefficient of the X-rays and is directly correlated to tissue density [15] . CT has proven to be a useful complementary tool when combined with other modalities of functional imaging, since it provides structural information that makes it possible to accurately locate activity distribution within the body of a living animal.
We used PET and CT scanners to assess both the anatomical distribution and the amount of solution which reached the lungs immediately after transnasal delivery.
Materials and Methods

Animals and Experimental Protocol
Forty-six female BALB/c mice were used in the experiment. Animals were purchased from IFFA CREDO SA (Barcelona, Spain), maintained at a constant temperature (24±0.5°C) under a 12-h light/dark cycle, and permitted free access to commercial rodent laboratory chow and water. The following three groups were established based on volume administered and age: Once mice were anesthetized with inhaled Forane® (Abbott Laboratories Ltd., Kent, UK), they were placed upright and received the positron-emitting tracer 2-deoxy-2-[ .69 MBq) of saline. Animals were administered half the volume through each nostril with a micropipette and were kept upright for~30 s to facilitate the access of the tracer to the airway. One minute after the instillation, the mice were anesthetized with isofluorane (5% for induction and 2% for maintenance in 100% O 2 ) and were introduced in the PET scanner in head-in prone position. The mice were dynamically scanned for 320 s, generating a study with eight frames of 40 s each. Moreover, ten mice from group B were also scanned using a static whole body imaging protocol of 320 s with two bed positions and one frame to check that the solution did not enter compartments other than the lungs or upper airways.
All experimental animal procedures were performed in compliance with the European Communities Council Directive of 24 November 1986 (86/609/EEC) and were approved by the Institutional Animal Care and Use Committee of the Hospital.
PET Imaging
PET scans were performed with a small-animal PET scanner (rPET SUINSA Medical Systems, Madrid, Spain) [15] , and acquisitions were centered on the thoracic region. Tomographic images were reconstructed using a 3D-FBP (filtered back projection) algorithm that produced 55 slices measuring 55×55 pixels each. In the case of whole body imaging protocol, the study had 102 slices of 55× 55 pixels. The voxel size was 0.81×0.81×0.81 mm 3 , and the spatial resolution in these images was 1.65 mm full width at halfmaximum isotropic. The energy window was 400-700 keV, and decay, deadtime, randoms, and scatter corrections were applied. Attenuation correction was not performed since the attenuation correction factor for mouse lungs should be close to 1 due to the very low amount of tissue present on the thoracic tomographic slices. Previous studies [19] have demonstrated that it is possible to perform accurate quantification of 18 FDG PET images of small mice without attenuation correction even in more dense tissues as the liver. Therefore, we assume that attenuation correction would not significantly change the quantitative results.
Analysis of PET Data
To obtain quantitative data of lung activity, three regions of interest (ROI) were drawn on coronal, sagittal, and transaxial sections of the dynamic studies: right lung, left lung, and total field of view (FOV) activity. Time-activity curves were obtained and extrapolations to time 0 were calculated by fitting the data to an exponential function. These values at time=0 were used to estimate the initial distribution, specifically the fraction of the activity going to the lungs with respect to the injected dose (represented by the total FOV activity). Results are thus presented as a percentage of total FOV activity. Figure 1 shows an example of these timeactivity curves in a mouse instilled with 30 μl.
CT Study
Those animals scanned using a PET whole body imaging protocol were also scanned on a small animal CT scanner [16] . CT images covered the animal from nose to abdomen and were reconstructed using a modified Feldkamp, Davis, and Kress algorithm. The voxel size was 0.25×0.25×0.25 mm 3 . Tube current and amperage (50 kV, 200 μA) were optimized for lung imaging.
The tracheal volume in a subgroup of eight animals from group B was obtained from the CT images by drawing on coronal sections an ROI corresponding to the tracheal lumen.
CT and PET images were co-registered using a marker-based rigid registration method to obtain an initial realignment, followed by a refinement step based on an automatic mutual information registration algorithm [2, 10] .
Statistical Analysis
ROI data were analyzed by means of one-way analysis of variance (ANOVA) followed by post hoc tests (Scheffé). Hypothesis of normality of distributions and homogeneity of variance were assessed using the Kolmogorov-Smirnov and Levene tests, respectively.
Results
An average of 5.69±4.51% (mean±SD) of the administered solution reached the lungs in group A, 41.84±8.03% in group B and 36.65±16.15% in group C. All the studies included the animal head well inside the field of view. The proportion of solution delivered to each lung in the different groups is summarized in Table 1. ANOVA revealed a significant difference between groups in the total proportion of administered solution that reached the lungs, depending on injection volume (PG0.001), but not on animal age. No significant differences in the distribution of the solution were observed between the left and right lungs in any of the groups.
The percentage of solution reaching the lungs showed very low values (G4%) in four animals from group A. The tracheal volume of mice 8-10 weeks old was 13.6± 1.8 μl.
The co-registered PET and CT studies of mice scanned using a whole body imaging position protocol confirmed the anatomical location of the tracer after transnasal administration. Activity was detected in lungs, trachea, and upper airways (nose, throat), but not in the gastrointestinal tract (Fig. 3) . Figure 4 shows combined PET-CT axial sections of a representative mouse after transnasal administration of 30 μl containing approximately 300 μCi.
Discussion
The study of in vivo animal models has provided valuable information on several aspects of the pathogenesis and treatment of allergy and asthma. Murine models of allergic asthma have usually been generated by inducing systemic sensitization followed by an airway challenge using nebulized or transnasal allergen [4, 20] . In the present study, we evaluated the amount of solution reaching the lung and its distribution within the airways after a transnasal challenge by 18 FDG by PET and CT imaging. In this study, we used an aqueous solution of FDG to examine the anatomical distribution of the dose after intranasal administration. The activity of FDG decreased with time, as shown in Fig. 1 , probably due to the diffusion of FDG into the bloodstream and posterior uptake by different tissues. The acquisition duration of our study (about 5 min) was too short to see clear FDG uptake in any specific organ. The study of this diffusion and redistribution process is not of interest in this work; therefore, we used time=0 extrapolated values to estimate the initial dose distribution.
In our work, we assume that immediately after the administration of FDG, all the dose remains in the FOV, which covers the upper respiratory tract, lungs, esophagus, and stomach. In this regard, any other tracer could have been used instead of FDG, as any specific metabolization of the radiopharmaceutical is irrelevant at time=0 when the initial distribution only depends on physical mechanisms.
The influence of the age of the mice on the tracer distribution was also evaluated. Mice are born without alveoli, and these are formed rapidly within the first few postnatal weeks [1] . The development of the alveoli and the elastic fiber is complete by 38 days of age [8] . The present study was performed on animals with fully developed alveoli. We studied animals that were 8 to 10 weeks old (young adults) and 32 weeks old (old adults). Young adults are usually used for acute asthma studies and old adults are used in chronic asthmatic models. We did not detect any age-related differences in tracer distribution in the lungs of the animals that received 30 μl, indicating that transnasal challenge may be valuable in both acute and chronic models.
Efficiency of dose delivery to the lung can be defined as the percentage of the dose deposited in the lungs (dl) relative to the dose delivered (dd) [ (Table 1 ; Efficiency=100×dl/ dd)]. After administering the allergen transnasally with the animal supine and its neck hyperextended, Tomaki et al. [13] reported that 31% of administered particles finished in the lower airways. In this study, the efficiency of transnasal administration was examined using Evans blue dye and isolating tissue from the trachea, bronchi, lungs, esophagus, stomach, and nose. Our study is the first to use an in vivo molecular imaging technique (PET) to evaluate the efficiency of transnasal challenge in mice, and we obtained an overall value in the lungs close to 40% of the delivered dose. The regional distribution of FDG in the lungs was apparently homogenous, but no attempt was made to perform a quantitative assessment.
The optimum volume instilled for challenge is a controversial issue. In some protocols, the instilled volumes ranged from 50 μl [5, 9, 12] to 100 μl over several days [6] . Other authors use only 10 μl over several days [14] . We compared the effect of two different volumes of instillation, 15 and 30 μl, and found significant differences between them: The animals that received 15 μl showed approximately 35% less activity in the lungs than those that received 30 μl. These results agree with the data shown by Tomaki et al. [13] who reported that 31% of the dose went into the lungs with 25 μl. In our case, when we administered 30 μl, the amount of tracer in the lungs reached about 40%. We obtained a tracheal volume of about 13.6±1.8 μl in mice aged 8-10 weeks. This volume could explain the approximately sixfold difference in mean lung distribution between animals from group A and groups B/C, as it implies that a minimum volume of 30 μl may be necessary in order to ensure that at least 40% of the administered dose actually reaches the lungs. This result is interesting, since it is necessary to find a compromise between the volume administered (trying not to drown the animal) and the amount of allergen/medication that reaches the lungs. We had previously tried administering 50 μl, but some mice died (data not shown). In fact, we have demonstrated that the instillation of allergen in a volume of 30 μl can induce lung inflammation in airway disease models at a lower risk of drowning [4] .
In those cases of group A where the dose reaching the lungs was very low, most of the FDG solution appeared at the upper nasal passages and esophagus. This probably means that either the positioning for instillation, the instillation duration, or the instilled volume was not technically adequate. In this way, the large variation within and between groups may reflect the technical difficulty of the nasal administration, which sometimes even leads to a totally incorrect dose delivery, particularly when the instilled volume is small, as is the case with group A. According to this interpretation, a proper instillation technique may constitute a key point of the procedure, and a number of failures in the administration have to be accepted as a possibility by the experimenters.
Our study showed the advantage of using multimodality image registration (PET and CT studies). PET allowed us to quantify the distribution of the tracer administered transnasally in the upper airways (nose, throat), trachea, and the lungs (Fig. 3) . CT images provide anatomical information that, co-registered with PET, enabled us to demonstrate that the solution reaches the anatomical target in a sufficient amount.
One possible limitation of our study derives from the extrapolation of time-activity curves to time=0 by fitting data to an exponential function. We chose an exponential function because of its good fit to our data and because it is a simple and robust model. We did not test whether another function could yield more precise results.
We believe that the information provided by these results may be of interest for researchers working in the field of airway allergen challenge, as there is no available data on the amount of allergen that may really reach the lung in in vivo studies. It may also be advisable for the researchers to be aware about the possibility of an incorrect instillation that may lead to a near-zero dose delivered to the lung in a small percentage of the cases.
In conclusion, in this first report on quantitative imaging by PET and CT in small animals, we confirmed that the transnasal route with an instilled volume of 30 μl is suitable for delivering fluids into the lower airways, although only about 40% of the dose reaches the lungs.
